$MNKD
MANNKIND CORP Stock $mnkd

$mnkd Overview Financials Valuation SEC Filings Company Website

2016 Form 10-K Financial Statement

#000119312517085519 Filed on March 16, 2017

Income Statement

Concept	2016	2015 Q4	2015 Q3
Revenue	$174.8M	$0.00	$0.00
YoY Change
Cost Of Revenue	$17.12M	$51.80M	$8.115M
YoY Change	-73.56%
Gross Profit	$157.6M	-$51.80M	-$8.115M
YoY Change	-343.47%
Gross Profit Margin	90.2%
Selling, General & Admin	$46.93M	$8.300M	$11.55M
YoY Change	14.57%	-33.6%	-39.54%
% of Gross Profit	29.77%
Research & Development	$14.92M	$6.200M	$6.341M
YoY Change	-49.73%	-64.77%	-66.94%
% of Gross Profit	9.46%
Depreciation & Amortization	$2.400M	$3.190M	$3.165M
YoY Change	-78.18%	5.98%	29.24%
% of Gross Profit	1.52%
Operating Expenses	$61.85M	$14.50M	$26.00M
YoY Change	-82.06%	-51.83%	-32.05%
Operating Profit	$67.26M	-$66.30M	-$26.00M
YoY Change	-119.52%		-32.05%
Interest Expense	-$9.600M	-$4.100M	-$4.900M
YoY Change	-139.83%	-35.94%	-20.97%
% of Operating Profit	-14.27%
Other Income/Expense, Net	$58.40M	-$100.0K	$67.00K
YoY Change	-345.5%		-99.15%
Pretax Income	$125.7M	-$277.0M	-$31.86M
YoY Change	-134.11%	660.99%	-12.77%
Income Tax	$0.00	$0.00	$0.00
% Of Pretax Income	0.0%
Net Earnings	$125.7M	-$277.0M	-$31.86M
YoY Change	-134.11%	660.23%	-12.77%
Net Earnings / Revenue	71.91%
Basic Earnings Per Share	$1.37		-$0.08
Diluted Earnings Per Share	$1.36	-$3.302M	-$0.08
COMMON SHARES
Basic Shares Outstanding	92.05M	409.5M shares	405.2M shares
Diluted Shares Outstanding	92.09M		405.2M shares

Balance Sheet

Concept	2016	2015 Q4	2015 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments	$22.90M	$59.10M	$32.90M
YoY Change	-61.25%	-51.08%	-80.93%
Cash & Equivalents	$22.90M	$59.07M	$32.93M
Short-Term Investments
Other Short-Term Assets	$21.40M	$17.50M	$13.20M
YoY Change	22.29%	-13.37%	-34.98%
Inventory	$2.300M	$0.00	$23.40M
Prepaid Expenses		$15.00M
Receivables	$300.0K	$23.00K	$1.679M
Other Receivables	$30.60M	$0.00	$0.00
Total Short-Term Assets	$77.50M	$76.65M	$71.24M
YoY Change	1.04%	-61.89%	-63.19%
LONG-TERM ASSETS
Property, Plant & Equipment	$28.90M	$48.75M	$191.4M
YoY Change	-40.66%	-74.63%	0.25%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$600.0K	$1.009M	$1.831M
YoY Change	-40.0%	18.99%	-13.39%
Total Long-Term Assets	$29.60M	$49.76M	$206.8M
YoY Change	-40.44%	-74.26%	6.97%
TOTAL ASSETS
Total Short-Term Assets	$77.50M	$76.65M	$71.24M
Total Long-Term Assets	$29.60M	$49.76M	$206.8M
Total Assets	$107.1M	$126.4M	$278.0M
YoY Change	-15.27%	-67.95%	-28.13%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$3.300M	$15.60M	$4.444M
YoY Change	-78.85%	110.97%	-74.44%
Accrued Expenses	$7.600M	$7.929M	$14.08M
YoY Change	20.63%	-69.74%	-48.36%
Deferred Revenue
YoY Change
Short-Term Debt	$71.30M	$74.60M	$74.20M
YoY Change	-4.42%	2.19%
Long-Term Debt Due		$0.00	$0.00
YoY Change		-100.0%	-100.0%
Total Short-Term Liabilities	$92.10M	$268.3M	$267.3M
YoY Change	-65.67%	-33.48%	-9.01%
LONG-TERM LIABILITIES
Long-Term Debt	$77.20M	$139.5M	$120.8M
YoY Change	-44.66%	165.21%	-1.06%
Other Long-Term Liabilities	$121.4M	$15.23M	$14.50M
YoY Change	76.2%	23.77%	25.26%
Total Long-Term Liabilities	$198.6M	$15.23M	$14.50M
YoY Change	-4.7%	23.77%	25.26%
TOTAL LIABILITIES
Total Short-Term Liabilities	$92.10M	$268.3M	$267.3M
Total Long-Term Liabilities	$198.6M	$15.23M	$14.50M
Total Liabilities	$290.7M	$476.7M	$402.6M
YoY Change	-39.02%	1.82%	-5.83%
SHAREHOLDERS EQUITY
Retained Earnings		-$2.863B	-$2.586B
YoY Change		14.77%
Common Stock		$2.513B	$2.462B
YoY Change		3.8%	1.82%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	-$183.6M	-$350.3M	-$124.6M
YoY Change
Total Liabilities & Shareholders Equity	$107.1M	$126.4M	$278.0M
YoY Change	-15.27%	-67.95%	-28.13%

Cashflow Statement

Concept	2016	2015 Q4	2015 Q3
OPERATING ACTIVITIES
Net Income	$125.7M	-$277.0M	-$31.86M
YoY Change	-134.11%	660.23%	-12.77%
Depreciation, Depletion And Amortization	$2.400M	$3.190M	$3.165M
YoY Change	-78.18%	5.98%	29.24%
Cash From Operating Activities	-$78.09M	-$22.55M	-$19.89M
YoY Change	36.45%	-36.91%	-119.84%
INVESTING ACTIVITIES
Capital Expenditures	$1.144M	-$320.0K	-$1.230M
YoY Change	-88.88%	-93.56%	-87.0%
Acquisitions
YoY Change
Other Investing Activities	$20.00K	$0.00	$80.00K
YoY Change	-75.0%	-100.0%	-99.14%
Cash From Investing Activities	-$1.127M	-$310.0K	-$1.150M
YoY Change	-88.95%	-97.82%	447.62%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net	$893.0K
YoY Change	-96.85%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	43.04M	49.01M	-53.21M
YoY Change	659.05%	-3034.73%	-270.38%
NET CHANGE
Cash From Operating Activities	-78.09M	-22.55M	-19.89M
Cash From Investing Activities	-1.127M	-310.0K	-1.150M
Cash From Financing Activities	43.04M	49.01M	-53.21M
Net Change In Cash	-36.18M	26.15M	-74.25M
YoY Change	-41.42%	-150.65%	-156.57%
FREE CASH FLOW
Cash From Operating Activities	-$78.09M	-$22.55M	-$19.89M
Capital Expenditures	$1.144M	-$320.0K	-$1.230M
Free Cash Flow	-$79.23M	-$22.23M	-$18.66M
YoY Change	17.36%	-27.75%	-117.01%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2012Q1	mnkd	Units Sold Under Public Offer Underwritten UnitsSoldUnderPublicOfferUnderwritten	7187500	shares
CY2012Q1	mnkd	Units Sold Warrant Portion Convertible Into Common Stock UnitsSoldWarrantPortionConvertibleIntoCommonStock	0.1
CY2015Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2015Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue	24.25
CY2015Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	110000000	shares
CY2015Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	85734188	shares
CY2015Q4	us-gaap	Ownshare Lending Arrangement Shares Outstanding OwnshareLendingArrangementSharesOutstanding	1800000	shares
CY2015Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.05
CY2015Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	85734188	shares
CY2015Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2015Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	3955845	shares
CY2015Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	22.70
CY2015Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2015Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2015Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber	360924	shares
CY2015Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-2863229000
CY2015Q4	us-gaap	Preferred Stock Value PreferredStockValue
CY2015Q4	us-gaap	Loss Contingency Accrual Carrying Value Noncurrent LossContingencyAccrualCarryingValueNoncurrent	62371000
CY2015Q4	us-gaap	Liabilities Liabilities	476741000
CY2015Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	126412000
CY2015Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	2634000
CY2015Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-20000
CY2015Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	15599000
CY2015Q4	us-gaap	Stockholders Equity StockholdersEquity	-350329000
CY2015Q4	us-gaap	Restructuring Reserve RestructuringReserve	3028000
CY2015Q4	us-gaap	Notes Payable Related Parties Noncurrent NotesPayableRelatedPartiesNoncurrent	49521000
CY2015Q4	us-gaap	Interest Payable Current InterestPayableCurrent	615000
CY2015Q4	us-gaap	Common Stock Value CommonStockValue	4287000
CY2015Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	2508633000
CY2015Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	119513000
CY2015Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	931000
CY2015Q4	us-gaap	Restructuring Reserve Current RestructuringReserveCurrent	3028000
CY2015Q4	us-gaap	Construction Payable Current ConstructionPayableCurrent	238000
CY2016Q4	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	13.05
CY2015Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	962623000
CY2015Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	0
CY2015Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Other DeferredTaxAssetsTaxDeferredExpenseOther	7186000
CY2015Q4	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	0
CY2015Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	1009000
CY2015Q4	mnkd	Shares Reserved For Employee Stock Purchase Plan SharesReservedForEmployeeStockPurchasePlan	140000	shares
CY2015Q4	mnkd	Deferred Collaborative Credit Current DeferredCollaborativeCreditCurrent	140231000
CY2015Q4	mnkd	Accrued Interest Noncurrent AccruedInterestNoncurrent	6380000
CY2015Q4	mnkd	Milestone Rights Liability And Other Liabilities Noncurrent MilestoneRightsLiabilityAndOtherLiabilitiesNoncurrent	8845000
CY2015Q4	mnkd	Deferred Tax Assets Tax Deferred Expense Accrual Adjustment DeferredTaxAssetsTaxDeferredExpenseAccrualAdjustment	251000
CY2016Q2	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	7.50
CY2015Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2015Q4	us-gaap	Other Long Term Debt Current OtherLongTermDebtCurrent	74582000
CY2015Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	483000
CY2015Q4	us-gaap	Liabilities Current LiabilitiesCurrent	268319000
CY2015Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	962623000
CY2015Q4	us-gaap	Convertible Long Term Notes Payable ConvertibleLongTermNotesPayable	27613000
CY2015Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	7929000
CY2015Q4	us-gaap	Assets Current AssetsCurrent	76654000
CY2015Q4	us-gaap	Deferred Tax Assets Deferred Income DeferredTaxAssetsDeferredIncome	52484000
CY2015Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	48755000
CY2015Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	48749000
CY2015Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	59074000
CY2015Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	721588000
CY2015Q4	us-gaap	Accounts And Other Receivables Net Current AccountsAndOtherReceivablesNetCurrent	23000
CY2015Q4	us-gaap	Deferred Costs Current DeferredCostsCurrent	13539000
CY2015Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	73646000
CY2015Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	16941000
CY2015Q4	us-gaap	Money Market Funds At Carrying Value MoneyMarketFundsAtCarryingValue	55800000
CY2015Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	168262000
CY2015Q4	us-gaap	Assets Assets	126412000
CY2015Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	4018000
CY2015Q4	mnkd	Deferred Tax Assets Capitalized Research Expenses DeferredTaxAssetsCapitalizedResearchExpenses	5872000
CY2015Q4	mnkd	Deferred Tax Assets Loss On Purchase Commitment DeferredTaxAssetsLossOnPurchaseCommitment	24084000
CY2015Q4	mnkd	Purchase Obligation Noncurrent PurchaseObligationNoncurrent	53692000
CY2015Q4	mnkd	Accrued Interest Of Related Party Debt AccruedInterestOfRelatedPartyDebt	6400000
CY2015Q4	mnkd	Deferred Collaborative Revenue Current DeferredCollaborativeRevenueCurrent	17503000
CY2015Q4	mnkd	Deferred Tax Assets Milestone Rights DeferredTaxAssetsMilestoneRights	3242000
CY2015Q4	mnkd	Estimated Amounts Credit Exchange Receivable EstimatedAmountsCreditExchangeReceivable	743000
CY2015Q4	mnkd	Purchase Obligation Current PurchaseObligationCurrent	12475000
CY2015Q4	mnkd	Deferred Tax Assets Capitalized Costs DeferredTaxAssetsCapitalizedCosts	8574000
CY2016Q2	us-gaap	Liabilities Fair Value Disclosure LiabilitiesFairValueDisclosure	44700000
CY2016Q4	us-gaap	Preferred Stock Value PreferredStockValue
CY2016Q4	us-gaap	Liabilities Liabilities	290656000
CY2016Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	107063000
CY2016Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	3814000
CY2016Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	875000
CY2016Q4	us-gaap	Restructuring Reserve Current RestructuringReserveCurrent	1376000
CY2016Q4	us-gaap	Purchase Obligation Due In Third Year PurchaseObligationDueInThirdYear	11600000
CY2016Q4	us-gaap	Purchase Obligation Due In Fifth Year PurchaseObligationDueInFifthYear	15500000
CY2016Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Two LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo	20000000
CY2016Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2016Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2016Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue	8.40
CY2016Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice	16.35
CY2016Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	140000000	shares
CY2016Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	95680831	shares
CY2016Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant	3840587	shares
CY2016Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	5399777	shares
CY2016Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.05
CY2016Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	95680831	shares
CY2016Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2016Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	3414586	shares
CY2016Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	22.50
CY2016Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	5530256	shares
CY2016Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	16.10
CY2016Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2016Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2016Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber	737966	shares
CY2016Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-2737565000
CY2016Q4	us-gaap	Purchase Obligation PurchaseObligation	116200000
CY2016Q4	us-gaap	Derivative Liabilities Noncurrent DerivativeLiabilitiesNoncurrent	7381000
CY2016Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	3419000
CY2016Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-24000
CY2016Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	3263000
CY2016Q4	us-gaap	Stockholders Equity StockholdersEquity	-183593000
CY2016Q4	us-gaap	Restructuring Reserve RestructuringReserve	1376000
CY2016Q4	us-gaap	Purchase Obligation Due In Second Year PurchaseObligationDueInSecondYear	8900000
CY2016Q4	us-gaap	Notes Payable Related Parties Noncurrent NotesPayableRelatedPartiesNoncurrent	49521000
CY2016Q4	us-gaap	Interest Payable Current InterestPayableCurrent	619000
CY2016Q4	us-gaap	Common Stock Value CommonStockValue	4784000
CY2016Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	2549212000
CY2016Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	99575000
CY2016Q4	us-gaap	Purchase Obligation Due In Fourth Year PurchaseObligationDueInFourthYear	15500000
CY2016Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	355000
CY2016Q4	us-gaap	Purchase Obligation Due In Next Twelve Months PurchaseObligationDueInNextTwelveMonths	2700000
CY2016Q4	us-gaap	Other Long Term Debt Current OtherLongTermDebtCurrent	71339000
CY2016Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Four LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour	35000000
CY2016Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Three LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree	20000000
CY2016Q4	us-gaap	Liabilities Current LiabilitiesCurrent	92051000
CY2016Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	914498000
CY2016Q4	us-gaap	Convertible Long Term Notes Payable ConvertibleLongTermNotesPayable	27635000
CY2016Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	7937000
CY2016Q4	us-gaap	Assets Current AssetsCurrent	77488000
CY2016Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards State And Local DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal	1300000000
CY2016Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	45310000
CY2016Q4	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	2120000
CY2016Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	28927000
CY2016Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	0
CY2016Q4	us-gaap	Assets Held For Sale Not Part Of Disposal Group Current AssetsHeldForSaleNotPartOfDisposalGroupCurrent	16730000
CY2016Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	22895000
CY2016Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	712124000
CY2016Q4	us-gaap	Inventory Net InventoryNet	2331000
CY2016Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue	2000
CY2016Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	302000
CY2016Q4	us-gaap	Accounts And Other Receivables Net Current AccountsAndOtherReceivablesNetCurrent	30557000
CY2016Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards Domestic DeferredTaxAssetsOperatingLossCarryforwardsDomestic	1900000000
CY2016Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	77998000
CY2016Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	17331000
CY2016Q4	us-gaap	Money Market Funds At Carrying Value MoneyMarketFundsAtCarryingValue	20500000
CY2016Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	128502000
CY2016Q4	us-gaap	Assets Assets	107063000
CY2016Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	914498000
CY2016Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	0
CY2016Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Other DeferredTaxAssetsTaxDeferredExpenseOther	7380000
CY2016Q4	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	0
CY2016Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	211000
CY2016Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	648000
CY2016Q4	us-gaap	Other Deferred Costs Net OtherDeferredCostsNet	309000
CY2016Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	4364000
CY2016Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	2000
CY2016Q4	mnkd	Weighted Average Grant Date Fair Value Of Restricted Stock Units Expected To Vest WeightedAverageGrantDateFairValueOfRestrictedStockUnitsExpectedToVest	8.60
CY2016Q4	mnkd	Sales And Marketing Related Expenses Accrued SalesAndMarketingRelatedExpensesAccrued	144000
CY2016Q4	mnkd	Deferred Tax Assets Capitalized Research Expenses DeferredTaxAssetsCapitalizedResearchExpenses	5117000
CY2016Q4	mnkd	Share Based Compensation Arrangement Restricted Stock Units Number Of Units Expected To Vest ShareBasedCompensationArrangementRestrictedStockUnitsNumberOfUnitsExpectedToVest	629424	shares
CY2016Q4	mnkd	Deferred Tax Assets Loss On Purchase Commitment DeferredTaxAssetsLossOnPurchaseCommitment	36775000
CY2016Q4	mnkd	Cash Discount Percent CashDiscountPercent	0.02	pure
CY2016Q4	mnkd	Customer Discounts And Allowances CustomerDiscountsAndAllowances	754000
CY2016Q4	mnkd	Purchase Obligation Current PurchaseObligationCurrent	5093000
CY2016Q4	mnkd	Deferred Tax Assets Capitalized Costs DeferredTaxAssetsCapitalizedCosts	8781000
CY2016Q4	mnkd	Purchase Obligation Noncurrent PurchaseObligationNoncurrent	95942000
CY2016Q4	mnkd	Accrued Interest Of Related Party Debt AccruedInterestOfRelatedPartyDebt	9300000
CY2016Q4	mnkd	Deferred Tax Assets Milestone Rights DeferredTaxAssetsMilestoneRights	3242000
CY2016Q4	mnkd	Estimated Amounts Credit Exchange Receivable EstimatedAmountsCreditExchangeReceivable	246000
CY2015	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	5946249	shares
CY2015	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-4.54
CY2016Q4	mnkd	Deferred Collaborative Credit Current DeferredCollaborativeCreditCurrent	1000000
CY2015	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.350	pure
CY2015	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.340	pure
CY2016Q4	mnkd	Purchase Obligation Due In Sixth Year PurchaseObligationDueInSixthYear	19400000
CY2016Q4	mnkd	Accrued Interest Noncurrent AccruedInterestNoncurrent	9281000
CY2016Q4	mnkd	Milestone Rights Liability And Other Liabilities Noncurrent MilestoneRightsLiabilityAndOtherLiabilitiesNoncurrent	8845000
CY2016Q4	mnkd	Deferred Tax Assets Tax Deferred Expense Accrual Adjustment DeferredTaxAssetsTaxDeferredExpenseAccrualAdjustment	440000
CY2016Q4	mnkd	Purchase Obligation Due In Seventh Year PurchaseObligationDueInSeventhYear	19400000
CY2017Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	95776246	shares
CY2004Q3	mnkd	Operating Loss Carryforwards Subject To Limitation OperatingLossCarryforwardsSubjectToLimitation	216000000
CY2015Q4	mnkd	Shares Returned Under Share Lending Agreement SharesReturnedUnderShareLendingAgreement	1800000	shares
CY2015Q4	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	31860	shares
CY2016Q2	dei	Entity Public Float EntityPublicFloat	372097776
CY2016Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	700000000	shares
CY2013Q4	us-gaap	Stockholders Equity StockholdersEquity	-30713000
CY2013Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	70790000
CY2014Q4	us-gaap	Stockholders Equity StockholdersEquity	-73770000
CY2014Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	120841000
CY2014Q4	mnkd	Estimated Amounts Credit Exchange Receivable EstimatedAmountsCreditExchangeReceivable	816000
CY2014Q4	mnkd	Shares Reserved For Employee Stock Purchase Plan SharesReservedForEmployeeStockPurchasePlan	140000	shares
CY2012Q1	mnkd	Proceeds From Issuance Of Common Stock And Warrants ProceedsFromIssuanceOfCommonStockAndWarrants	80600000
CY2015Q4	mnkd	Class Of Warrant Exercise Price Of Warrants Stated As Percentage Of Offering Price ClassOfWarrantExercisePriceOfWarrantsStatedAsPercentageOfOfferingPrice	0.0115	pure
CY2004Q1	mnkd	Percentage Of Common Stock Shares Outstanding PercentageOfCommonStockSharesOutstanding	0.01	pure
CY2004Q3	mnkd	Net Operating Loss Carryforward Annual Limitation NetOperatingLossCarryforwardAnnualLimitation	13000000
CY2015	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-57232000
CY2015	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum	0.7184	pure
CY2015	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	81233000	shares
CY2015	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	81233000	shares
CY2015	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0.00	pure
CY2015	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum	0.6976	pure
CY2015	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum	0.0161	pure
CY2015	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P5Y2M19D
CY2015	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	12.80
CY2015	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-4.54
CY2015	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	-0.010	pure
CY2015	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum	0.0186	pure
CY2015	us-gaap	Stock Issued During Period Shares Employee Stock Purchase Plans StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans	64245	shares
CY2015	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.00	pure
CY2015	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	80100000
CY2015	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	10285000
CY2015	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax	-6000
CY2015	us-gaap	Increase Decrease In Accounts And Other Receivables IncreaseDecreaseInAccountsAndOtherReceivables	-50413000
CY2015	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-1049000
CY2015	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-2697000
CY2015	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Restricted Stock Units Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition	-1856000
CY2015	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	7926000
CY2015	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	887000
CY2015	us-gaap	Repayments Of Senior Debt RepaymentsOfSeniorDebt	64287000
CY2015	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	548000
CY2015	us-gaap	Operating Income Loss OperatingIncomeLoss	-344655000
CY2015	us-gaap	Net Income Loss NetIncomeLoss	-368445000
CY2015	us-gaap	Loans Assumed1 LoansAssumed1	59337000
CY2015	us-gaap	Interest Paid InterestPaid	13355000
CY2015	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	-150000
CY2015	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	26434000
CY2015	us-gaap	Increase Decrease In Deferred Charges IncreaseDecreaseInDeferredCharges	13539000
CY2015	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-368451000
CY2015	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	8725000
CY2015	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	1858000
CY2015	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	831000
CY2015	us-gaap	Partners Capital Account Contributions PartnersCapitalAccountContributions	40000
CY2015	us-gaap	Investment Income Interest InvestmentIncomeInterest	18000
CY2015	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	3258000
CY2015	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	27843000
CY2015	us-gaap	Stock Issued1 StockIssued1	8253000
CY2015	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	1366000
CY2015	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-23790000
CY2015	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-13481000
CY2015	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-368445000
CY2015	us-gaap	Gain Loss On Disposition Of Assets GainLossOnDispositionOfAssets	-140582000
CY2015	us-gaap	Foreign Currency Transaction Gain Loss Realized ForeignCurrencyTransactionGainLossRealized	-2697000
CY2015	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	202000
CY2015	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	8725000
CY2015	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	109512000
CY2015	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-80118000
CY2015	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	-29394000
CY2015	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	11000000
CY2015	us-gaap	Impairment Of Long Lived Assets Held For Use ImpairmentOfLongLivedAssetsHeldForUse	140412000
CY2015	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0
CY2015	us-gaap	Increase Decrease In Customer Advances And Deposits IncreaseDecreaseInCustomerAdvancesAndDeposits	950000
CY2015	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	-12467000
CY2015	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	8413000
CY2015	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-10203000
CY2015	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	28392000
CY2015	us-gaap	Production Related Impairments Or Charges ProductionRelatedImpairmentsOrCharges	36104000
CY2015	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	82000
CY2015	us-gaap	Related Party Transaction Expenses From Transactions With Related Party RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty	2894000
CY2015	us-gaap	Share Based Compensation ShareBasedCompensation	8725000
CY2015	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	0
CY2015	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	0
CY2015	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	0
CY2015	us-gaap	Deferred Other Tax Expense Benefit DeferredOtherTaxExpenseBenefit	80118000
CY2015	us-gaap	Defined Benefit Plan Contributions By Employer DefinedBenefitPlanContributionsByEmployer	593000
CY2015	us-gaap	Depreciation And Amortization DepreciationAndAmortization	13276000
CY2015	us-gaap	Inventory Write Down InventoryWriteDown	39300000
CY2015	us-gaap	Paid In Kind Interest PaidInKindInterest	1652000
CY2015	us-gaap	Proceeds From Payments For Other Financing Activities ProceedsFromPaymentsForOtherFinancingActivities	40000
CY2015	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	29674000
CY2015	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	1587000
CY2015	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	40960000
CY2015	us-gaap	Costs And Expenses CostsAndExpenses	344655000
CY2015	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	39373000
CY2015	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	33000
CY2015	us-gaap	Interest Expense Debt InterestExpenseDebt	21231000
CY2015	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	5668000
CY2015	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	426000
CY2015	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	10123000
CY2015	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	6200000
CY2015	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options Aggregate Intrinsic Value Vested SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested	5200000
CY2015	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-61767000
CY2015	us-gaap	Cost Of Goods Sold CostOfGoodsSold	64745000
CY2015	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	0
CY2015	us-gaap	Deferred Foreign Income Tax Expense Benefit DeferredForeignIncomeTaxExpenseBenefit	0
CY2015	us-gaap	Employee Service Share Based Compensation Cash Received From Exercise Of Stock Options EmployeeServiceShareBasedCompensationCashReceivedFromExerciseOfStockOptions	3300000
CY2015	us-gaap	Impairment Charge On Reclassified Assets ImpairmentChargeOnReclassifiedAssets	140400000
CY2015	us-gaap	Interest Costs Capitalized InterestCostsCapitalized	100000
CY2015	us-gaap	Restructuring Charges RestructuringCharges	6040000
CY2015	us-gaap	Restructuring Reserve Settled Without Cash2 RestructuringReserveSettledWithoutCash2	3012000
CY2015	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Total Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue	5500000
CY2015	mnkd	Income Tax Expense Benefit Net IncomeTaxExpenseBenefitNet	0
CY2015	mnkd	Adjustments To Additional Paid In Capital Reclassification Of Warrants From Liability To Equity AdjustmentsToAdditionalPaidInCapitalReclassificationOfWarrantsFromLiabilityToEquity	109000
CY2015	mnkd	Increase Decrease In Deferred Collaborative Revenue IncreaseDecreaseInDeferredCollaborativeRevenue	17067000
CY2015	mnkd	Adjustments To Additional Paid In Capital Stock Option Issued Upon Debt Conversion AdjustmentsToAdditionalPaidInCapitalStockOptionIssuedUponDebtConversion	169000
CY2015	mnkd	Gain Loss On Purchase Commitments GainLossOnPurchaseCommitments	-66167000
CY2015	mnkd	Stock Issued During Period Value Warrant Exercises StockIssuedDuringPeriodValueWarrantExercises	10123000
CY2015	mnkd	Stock Issued During Period Value Share Lending Agreement StockIssuedDuringPeriodValueShareLendingAgreement	160000
CY2015	mnkd	Proceeds From Issuance Of Common Stock And Warrants Net ProceedsFromIssuanceOfCommonStockAndWarrantsNet	4146000
CY2015	mnkd	Payments For Use Of Aircrafts PaymentsForUseOfAircrafts	18000
CY2015	mnkd	Milestone Payments MilestonePayments	4219000
CY2015	mnkd	Interest On Note Payable To Principal Stockholder InterestOnNotePayableToPrincipalStockholder	2894000
CY2014	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	10292667	shares
CY2014	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-2.57
CY2014	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.350	pure
CY2014	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.318	pure
CY2014	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	4086000
CY2014	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum	0.8485	pure
CY2014	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	77045000	shares
CY2014	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	77045000	shares
CY2014	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0.00	pure
CY2014	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum	0.7398	pure
CY2014	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum	0.0164	pure
CY2014	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P2Y11M5D
CY2014	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	23.80
CY2014	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-2.57
CY2014	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	-0.041	pure
CY2014	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum	0.0211	pure
CY2014	us-gaap	Stock Issued During Period Shares Employee Stock Purchase Plans StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans	61015	shares
CY2014	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.00	pure
CY2014	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	65500000
CY2014	us-gaap	Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures	-26908000
CY2014	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	24097000
CY2014	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax	-10000
CY2014	us-gaap	Increase Decrease In Accounts And Other Receivables IncreaseDecreaseInAccountsAndOtherReceivables	50436000
CY2014	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	10000
CY2014	us-gaap	Debt Conversion Original Debt Amount1 DebtConversionOriginalDebtAmount1	93500000
CY2014	us-gaap	Construction In Progress Expenditures Incurred But Not Yet Paid ConstructionInProgressExpendituresIncurredButNotYetPaid	1768000
CY2014	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	1363000
CY2014	us-gaap	Operating Income Loss OperatingIncomeLoss	-179627000
CY2014	us-gaap	Net Income Loss NetIncomeLoss	-198382000
CY2014	us-gaap	Loans Assumed1 LoansAssumed1	3034000
CY2014	us-gaap	Interest Paid InterestPaid	11218000
CY2014	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	615000
CY2014	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	9670000
CY2014	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-198392000
CY2014	us-gaap	Adjustments To Additional Paid In Capital Other AdjustmentsToAdditionalPaidInCapitalOther	22962000
CY2014	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	25660000
CY2014	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	26908000
CY2014	us-gaap	Investment Income Interest InvestmentIncomeInterest	9000
CY2014	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	10978000
CY2014	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	1679000
CY2014	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-18755000
CY2014	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	14734000
CY2014	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-198382000
CY2014	us-gaap	Gain Loss On Disposition Of Assets GainLossOnDispositionOfAssets	-97000
CY2014	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	48622000
CY2014	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	57873000
CY2014	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-65504000
CY2014	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	7631000
CY2014	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	9800000
CY2014	us-gaap	Impairment Of Long Lived Assets Held For Use ImpairmentOfLongLivedAssetsHeldForUse	0
CY2014	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0
CY2014	us-gaap	Increase Decrease In Customer Advances And Deposits IncreaseDecreaseInCustomerAdvancesAndDeposits	200436000
CY2014	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	2276000
CY2014	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	3622000
CY2014	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-24097000
CY2014	us-gaap	Related Party Transaction Expenses From Transactions With Related Party RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty	2894000
CY2014	us-gaap	Share Based Compensation ShareBasedCompensation	48622000
CY2014	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	0
CY2014	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	0
CY2014	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	0
CY2014	us-gaap	Deferred Other Tax Expense Benefit DeferredOtherTaxExpenseBenefit	65504000
CY2014	us-gaap	Defined Benefit Plan Contributions By Employer DefinedBenefitPlanContributionsByEmployer	623000
CY2014	us-gaap	Depreciation And Amortization DepreciationAndAmortization	18575000
CY2014	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	100244000
CY2014	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	3556000
CY2014	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	79383000
CY2014	us-gaap	Costs And Expenses CostsAndExpenses	179627000
CY2014	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	75827000
CY2014	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	21000
CY2014	us-gaap	Interest Expense Debt InterestExpenseDebt	17549000
CY2014	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	70062000
CY2014	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	737000
CY2014	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	27779000
CY2014	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	14900000
CY2014	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options Aggregate Intrinsic Value Vested SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested	62700000
CY2014	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	50051000
CY2014	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	0
CY2014	us-gaap	Deferred Foreign Income Tax Expense Benefit DeferredForeignIncomeTaxExpenseBenefit	0
CY2014	us-gaap	Employee Service Share Based Compensation Cash Received From Exercise Of Stock Options EmployeeServiceShareBasedCompensationCashReceivedFromExerciseOfStockOptions	11000000
CY2014	us-gaap	Interest Costs Capitalized InterestCostsCapitalized	800000
CY2014	us-gaap	Proceeds From Issuance Of Debt ProceedsFromIssuanceOfDebt	40000000
CY2014	us-gaap	Proceeds From Issuance Of Long Term Debt ProceedsFromIssuanceOfLongTermDebt	20000000
CY2014	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Total Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue	36400000
CY2014	mnkd	Income Tax Expense Benefit Net IncomeTaxExpenseBenefitNet	0
CY2014	mnkd	Write Off Of Commitment Asset WriteOffOfCommitmentAsset	1753000
CY2014	mnkd	Write Off Of Derivative Liability WriteOffOfDerivativeLiability	363000
CY2014	mnkd	Common Stock Loaned Under Share Lending Agreement Shares CommonStockLoanedUnderShareLendingAgreementShares	1800000	shares
CY2014	mnkd	Stock Issued During Period Value For Debt Exchange StockIssuedDuringPeriodValueForDebtExchange	93501000
CY2014	mnkd	Effective Income Tax Rate Reconciliation Permanent Items EffectiveIncomeTaxRateReconciliationPermanentItems	0.009	pure
CY2014	mnkd	Stock Issued During Period Value Warrant Exercises StockIssuedDuringPeriodValueWarrantExercises	27779000
CY2014	mnkd	Proceeds From Issuance Of Common Stock And Warrants Net ProceedsFromIssuanceOfCommonStockAndWarrantsNet	12341000
CY2014	mnkd	Payments For Use Of Aircrafts PaymentsForUseOfAircrafts	79000
CY2014	mnkd	Milestone Payments MilestonePayments	3150000
CY2014	mnkd	Interest On Note Payable To Principal Stockholder InterestOnNotePayableToPrincipalStockholder	2894000
CY2014	mnkd	Nominal Lending Fee NominalLendingFee	0.05
CY2016	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	16788281	shares
CY2016	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2016	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2016
CY2016	dei	Document Type DocumentType	10-K
CY2016	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	1.36
CY2016	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.350	pure
CY2016	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.340	pure
CY2016	dei	Entity Central Index Key EntityCentralIndexKey	0000899460
CY2016	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2016	us-gaap	Incremental Common Shares Attributable To Contingently Issuable Shares IncrementalCommonSharesAttributableToContingentlyIssuableShares	32000	shares
CY2016	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-78090000
CY2016	us-gaap	Prior Period Reclassification Adjustment Description PriorPeriodReclassificationAdjustmentDescription	<div> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"> <i>Reclassifications</i> — Certain amounts from previous periods have been reclassified to conform to the 2016 presentation. Specifically, accrued interest — note payable to principal stockholder has been reclassified from the previously reported classification of other liabilities in the accompanying consolidated balance sheets. Additionally, the remaining balance from the previously reported classification of other liabilities is now identified as milestone rights liability, and is disclosed as a separate line item on the consolidated statements of cash flows. Additionally, on the consolidated statement of operations, product manufacturing has been renamed to cost of goods sold. The Company also reclassified (gain) loss on foreign currency translation from the previously reported classification of product manufacturing in the accompanying consolidated statements of operations. Additionally, certain balances from prepaid expenses and other current assets were reclassed to (gain) loss on foreign currency translation in the consolidated statements of cash flows.</p> </div>
CY2016	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum	0.8275	pure
CY2016	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod	199890	shares
CY2016	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	8.45
CY2016	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice	23.65
CY2016	dei	Trading Symbol TradingSymbol	MNKD
CY2016	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	92085000	shares
CY2016	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	92053000	shares
CY2016	dei	Amendment Flag AmendmentFlag	false
CY2016	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"> <i>Concentration of Credit Risk</i> — Financial instruments which potentially subject the Company to concentration of credit risk consist of cash and cash equivalents. Cash and cash equivalents are held in high credit quality institutions. Cash equivalents consist of interest-bearing money market accounts, which are regularly monitored by management.</p> </div>
CY2016	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod	292488	shares
CY2016	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0.00	pure
CY2016	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum	0.7757	pure
CY2016	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum	0.0118	pure
CY2016	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P5Y3M22D
CY2016	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	407161	shares
CY2016	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	3.05
CY2016	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	13.60
CY2016	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	4.50
CY2016	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2016	dei	Document Period End Date DocumentPeriodEndDate	2016-12-31
CY2016	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	1.37
CY2016	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	0.009	pure
CY2016	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2016	dei	Entity Filer Category EntityFilerCategory	Accelerated Filer
CY2016	us-gaap	Stock Repurchased During Period Shares StockRepurchasedDuringPeriodShares	43672	shares
CY2016	us-gaap	Revenue Recognition Deferred Revenue RevenueRecognitionDeferredRevenue	<div> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"> <i>Deferred Costs from Collaboration —</i> Deferred costs from collaboration represents the costs of product manufactured and sold to Sanofi, as well as certain direct costs associated with a firm purchase commitment entered into in connection with the collaboration with Sanofi. During the third quarter of 2016, the costs related to the Sanofi product sales were recognized as costs of revenue — collaboration in the consolidated statements of operations, as related revenue was recognized at that time.</p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"> <i>Deferred Costs from Commercial Product Sales —</i> Deferred costs from commercial product sales represents the cost of product (including labor, overhead and costs to ship to third party logistics) shipped to ICS and wholesale distributors, but not yet dispensed by pharmacies to patients.</p> </div>
CY2016	us-gaap	Revenue Recognition Discounts RevenueRecognitionDiscounts	<div> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:8%; text-indent:4%; font-size:10pt; font-family:Times New Roman"> <i>Prompt Pay Discounts —</i> The Company offers cash discounts to its customers, generally 2% of the sales price, as an incentive for prompt payment. The Company accounts for cash discounts by reducing accounts receivable by the prompt pay discount amount and recognizes the discount as a reduction of revenue in the same period the related revenue is recognized.</p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:8%; text-indent:4%; font-size:10pt; font-family:Times New Roman"> <i>Rebates —</i> The Company participates in federal and state government-managed Medicare and Medicaid rebate programs and intends to pursue participation in certain other qualifying federal and state government programs whereby discounts and rebates are provided to participating federal and state government entities. Rebates provided through these other qualifying programs are included in the Medicaid and Medicare rebate accrual. The Company accounts for these rebates by establishing an accrual equal to the estimate of rebate claims attributable to a sale and determines its estimate of the rebates accrual based on historical payor data provided by a third-party vendor along with additional data including a forecasted participation rate for Medicare and Medicaid. From that data, as well as input received from MannKind’s commercial team, an estimated participation rate for Medicare and Medicaid is determined and applied at the mandated rate for those sales. Any new information regarding changes in the programs’ regulations and guidelines or any changes in the Company’s government price reporting calculations that would impact the amount of the rebates will also be taken into account in determining or modifying the appropriate reserve. The time period between the date the product is sold into the channel and the date such rebates are paid ranges from approximately six to nine months. As such, continuous monitoring of these estimates are performed on a periodic basis and if necessary, adjusted to reflect new facts and circumstances. Rebates are recognized as a reduction of revenue in the period the related revenue is recognized.</p> </div>
CY2016	us-gaap	Revenue Recognition Multiple Element Arrangements RevenueRecognitionMultipleElementArrangements	<div> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman"> <i>Revenue Recognition — Net Revenue — Collaborations —</i> The Company enters into collaborations under which we must perform certain obligations and we receive periodic payments. We evaluate the collaborations under the multiple element revenue recognition accounting guidance. Revenue arrangements with multiple elements are divided into separate units of accounting if certain criteria are met, including whether the delivered elements have stand-alone value to the customer. When deliverables are separable, consideration received is allocated to the separate units of accounting based on the relative selling price of each deliverable and the appropriate revenue recognition principles are applied to each unit.</p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman"> The assessment of multiple element arrangements requires judgment in order to determine the appropriate units of accounting and the points in time that, or periods over which, revenue should be recognized. The terms of and the accounting for the Company’s collaborations are described more fully in Note 8 — Collaboration Arrangements.</p> </div>
CY2016	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	2236693	shares
CY2016	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeitures Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue	11.60
CY2016	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	4.50
CY2016	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum	0.0180	pure
CY2016	us-gaap	Stock Issued During Period Shares Employee Stock Purchase Plans StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans	104758	shares
CY2016	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	55231	shares
CY2016	us-gaap	Use Of Estimates UseOfEstimates	<div> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"> <i>Financial Statement Estimates</i> — The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America (GAAP) requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Actual results could differ from those estimates. Management considers many factors in selecting appropriate financial accounting policies, and in developing the estimates and assumptions that are used in the preparation of the financial statements. Management must apply significant judgment in this process. The more significant estimates reflected in these accompanying consolidated financial statements include revenue recognition, assessing long-lived assets for impairment, accrued expenses, including clinical study expenses, inventory recoverability, valuation of the facility financing obligation, loss on purchase commitment, warrant liability, milestone rights, stock-based compensation and the determination of the provision for income taxes and corresponding deferred tax assets and liabilities and any valuation allowance recorded against net deferred tax assets.</p> </div>
CY2016	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.00	pure
CY2016	dei	Entity Registrant Name EntityRegistrantName	MANNKIND CORP
CY2016	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2016	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P2Y10M24D
CY2016	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	-48100000
CY2016	us-gaap	Revenue Recognition Sales Of Goods RevenueRecognitionSalesOfGoods	<div> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman"> <i>Revenue Recognition — Net Revenue — Commercial Product Sales —</i> Between July 1, 2016 and December 15, 2016, the Company sold Afrezza to Integrated Commercialization Solutions Direct (ICS) and title and risk of loss transferred to ICS upon shipment. After December 15, 2016, ICS became a third party logistics provider and stopped taking title and risk of loss upon shipment of Afrezza to ICS. The Company sells Afrezza in the United States to wholesale pharmaceutical distributors through ICS, and ultimately to retail pharmacies, which are collectively referred to as “customers”.</p> <p style="font-size:1px;margin-top:6px;margin-bottom:0px">  </p> <p style="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman"> The Company provides the right of return to ICS (through December 15, 2016) and its wholesale distributors and, through them, to its retail pharmacy customers for unopened product for a period beginning six months prior to and ending twelve months after its expiration date. Once the product has been prescribed and dispensed to the patient, any right of return ceases to exist.</p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman"> Given the Company’s limited sales history for Afrezza, the Company cannot reliably estimate expected returns of the product at the time of shipment into the distribution channel. Accordingly, the Company defers recognition of revenue on Afrezza product shipments until the right of return no longer exists, which occurs at the earlier of the time Afrezza is dispensed from pharmacies to patients or expiration of the right of return. The Company recognizes revenue based on Afrezza patient prescriptions dispensed as estimated by syndicated data provided by a third party. The Company also analyzes additional data points to ensure that such third-party data is reasonable including data related to inventory movements within the channel and ongoing prescription demand.</p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman"> For the year ended December 31, 2016, net revenue from commercial product sales consisted of $1.9 million of net sales of Afrezza dispensed to patients. As of December 31, 2016, the Company recorded $3.4 million in deferred revenue on its consolidated balance sheet, of which $1.6 million (net of estimated <font style="white-space:nowrap"><font style="white-space:nowrap">gross-to-net</font></font> adjustments) represents product shipped to the Company’s third-party logistics provider and wholesale distributors, but not yet dispensed to patients. The difference represents deferred revenue from bulk insulin sales, which is described more fully under the heading <i>Revenue Recognition — Revenue — Bulk Insulin Sales</i> below.</p> </div>
CY2016	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Period1 ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1	P4Y
CY2016	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue	21.70
CY2016	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod	800530	shares
CY2016	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod	131000	shares
CY2016	us-gaap	Sales Revenue Net SalesRevenueNet	174758000
CY2016	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	1144000
CY2016	us-gaap	Payment Of Financing And Stock Issuance Costs PaymentOfFinancingAndStockIssuanceCosts	2690000
CY2016	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax	-4000
CY2016	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	72024000
CY2016	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	-600000
CY2016	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	3433000
CY2016	us-gaap	Construction In Progress Expenditures Incurred But Not Yet Paid ConstructionInProgressExpendituresIncurredButNotYetPaid	588000
CY2016	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Restricted Stock Units Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition	-165000
CY2016	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	426000
CY2016	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	1895000
CY2016	us-gaap	Operating Income Loss OperatingIncomeLoss	67260000
CY2016	us-gaap	Net Income Loss NetIncomeLoss	125664000
CY2016	us-gaap	Long Term Purchase Commitment Amount LongTermPurchaseCommitmentAmount	93000000
CY2016	us-gaap	Loans Assumed1 LoansAssumed1	5174000
CY2016	us-gaap	Interest Paid InterestPaid	8991000
CY2016	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	-361000
CY2016	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	2331000
CY2016	us-gaap	Increase Decrease In Deferred Charges IncreaseDecreaseInDeferredCharges	-13539000
CY2016	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	302000
CY2016	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	125660000
CY2016	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	5135000
CY2016	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	165000
CY2016	us-gaap	Investment Income Interest InvestmentIncomeInterest	85000
CY2016	us-gaap	Increase Decrease In Accounts And Notes Receivable IncreaseDecreaseInAccountsAndNotesReceivable	30534000
CY2016	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	467000
CY2016	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-597000
CY2016	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-19000
CY2016	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	58404000
CY2016	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	346000
CY2016	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	125664000
CY2016	us-gaap	Gain Loss On Disposition Of Assets GainLossOnDispositionOfAssets	-1259000
CY2016	us-gaap	Foreign Currency Transaction Gain Loss Realized ForeignCurrencyTransactionGainLossRealized	3433000
CY2016	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	12750000
CY2016	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	5135000
CY2016	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	-43814000
CY2016	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	48125000
CY2016	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	-4311000
CY2016	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	2400000
CY2016	us-gaap	Impairment Of Long Lived Assets Held For Use ImpairmentOfLongLivedAssetsHeldForUse	1259000
CY2016	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0
CY2016	us-gaap	Increase Decrease In Customer Advances And Deposits IncreaseDecreaseInCustomerAdvancesAndDeposits	-134056000
CY2016	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	348000
CY2016	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-12118000
CY2016	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-1127000
CY2016	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	17000
CY2016	us-gaap	Related Party Transaction Expenses From Transactions With Related Party RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty	2901000
CY2016	us-gaap	Share Based Compensation ShareBasedCompensation	5135000
CY2016	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	0
CY2016	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	0
CY2016	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	0
CY2016	us-gaap	Deferred Other Tax Expense Benefit DeferredOtherTaxExpenseBenefit	-48125000
CY2016	us-gaap	Defined Benefit Plan Contributions By Employer DefinedBenefitPlanContributionsByEmployer	418000
CY2016	us-gaap	Depreciation And Amortization DepreciationAndAmortization	4158000
CY2016	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	3419000
CY2016	us-gaap	Inventory Write Down InventoryWriteDown	200000
CY2016	us-gaap	Paid In Kind Interest PaidInKindInterest	4478000
CY2016	us-gaap	Proceeds From Issuance Of Private Placement ProceedsFromIssuanceOfPrivatePlacement	50000000
CY2016	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	14917000
CY2016	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	19854000
CY2016	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	46928000
CY2016	us-gaap	Costs And Expenses CostsAndExpenses	107498000
CY2016	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	27074000
CY2016	us-gaap	Interest Expense Debt InterestExpenseDebt	15576000
CY2016	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	43038000
CY2016	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	373000
CY2016	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	0
CY2016	us-gaap	Proceeds From Repayments Of Notes Payable ProceedsFromRepaymentsOfNotesPayable	-5000000
CY2016	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	100000
CY2016	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options Aggregate Intrinsic Value Vested SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested	600000
CY2016	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-36179000
CY2016	us-gaap	Cost Of Goods Sold CostOfGoodsSold	17121000
CY2016	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	0
CY2016	us-gaap	Deferred Foreign Income Tax Expense Benefit DeferredForeignIncomeTaxExpenseBenefit	0
CY2016	us-gaap	Employee Service Share Based Compensation Cash Received From Exercise Of Stock Options EmployeeServiceShareBasedCompensationCashReceivedFromExerciseOfStockOptions	500000
CY2016	us-gaap	Interest Costs Capitalized InterestCostsCapitalized	0
CY2016	us-gaap	Restructuring Charges RestructuringCharges	2035000
CY2016	us-gaap	Restructuring Reserve Settled Without Cash2 RestructuringReserveSettledWithoutCash2	3687000
CY2016	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Total Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue	2600000
CY2016	mnkd	Income Tax Expense Benefit Net IncomeTaxExpenseBenefitNet	0
CY2016	mnkd	Longterm Purchase Commitment Renewal Time Period LongtermPurchaseCommitmentRenewalTimePeriod	P2Y
CY2016	mnkd	Deferred Tax Asset Increase Decrease In Equity DeferredTaxAssetIncreaseDecreaseInEquity	11600000
CY2016	mnkd	Increase Decrease In Deferred Collaborative Revenue IncreaseDecreaseInDeferredCollaborativeRevenue	-17503000
CY2016	mnkd	Class Of Warrants Or Rights Expiration Date ClassOfWarrantsOrRightsExpirationDate	2016-02-08
CY2016Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.33
CY2016	mnkd	Class Of Warrant Or Right Exercised ClassOfWarrantOrRightExercised	0	shares
CY2016	mnkd	Maturity Period Of Cash Equivalents MaturityPeriodOfCashEquivalents	90 days or less at the time of purchase
CY2016	mnkd	Value Of Restricted Stock Units Vested ValueOfRestrictedStockUnitsVested	2000000
CY2016	mnkd	Adjustments To Additional Paid In Capital Shares Issued In Private Placement AdjustmentsToAdditionalPaidInCapitalSharesIssuedInPrivatePlacement	-2037000
CY2016	mnkd	Percentage Of Credit Exchange Receivable PercentageOfCreditExchangeReceivable	0.65	pure
CY2016	mnkd	Long Term Purchase Commitment Expiration Date LongTermPurchaseCommitmentExpirationDate	2023-12-31
CY2016	mnkd	Change In Fair Value Of Warrant Liability ChangeInFairValueOfWarrantLiability	5369000
CY2016	mnkd	Effective Income Tax Rate Reconciliation Permanent Items EffectiveIncomeTaxRateReconciliationPermanentItems	-0.019	pure
CY2016	mnkd	Gain Loss On Purchase Commitments GainLossOnPurchaseCommitments	2265000
CY2016	mnkd	Class Of Warrant Exercisable Period ClassOfWarrantExercisablePeriod	P5Y
CY2016	mnkd	Stock Options Granted Vesting Rate StockOptionsGrantedVestingRate	0.25	pure
CY2016	mnkd	Number Of Asset Groups NumberOfAssetGroups	2	asset_group
CY2016	mnkd	Proceeds From Issuance Of Common Stock And Warrants Net ProceedsFromIssuanceOfCommonStockAndWarrantsNet	893000
CY2016	mnkd	Payments For Use Of Aircrafts PaymentsForUseOfAircrafts	0
CY2016	mnkd	Warrant Issuance Costs WarrantIssuanceCosts	653000
CY2016	mnkd	Interest On Note Payable To Principal Stockholder InterestOnNotePayableToPrincipalStockholder	2901000
CY2016	mnkd	Net Revenue From Collaboration NetRevenueFromCollaboration	171965000
CY2016	mnkd	Increase Decrease In Other Deferred Charges IncreaseDecreaseInOtherDeferredCharges	309000
CY2016	mnkd	Increase Decrease In Purchase Commitment Loss IncreaseDecreaseInPurchaseCommitmentLoss	40566000
CY2016	mnkd	Reclassification Of Property Plant And Equipment To Assets Held For Sale Noncash ReclassificationOfPropertyPlantAndEquipmentToAssetsHeldForSaleNoncash	17294000
CY2016	mnkd	Deferred Cost Related To Sale Of Raw Insulin DeferredCostRelatedToSaleOfRawInsulin	0
CY2016	mnkd	Deferred Revenue From Sale Of Raw Insulin DeferredRevenueFromSaleOfRawInsulin	1800000
CY2016	mnkd	Common Stock And Warrants Issued In Direct Placement Value CommonStockAndWarrantsIssuedInDirectPlacementValue	50000000
CY2016	mnkd	Net Revenue From Bulk Insulin NetRevenueFromBulkInsulin	898000
CY2016	mnkd	Costs Of Revenue Collaboration CostsOfRevenueCollaboration	32971000
CY2016Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	1.32
CY2016Q3	us-gaap	Sales Revenue Net SalesRevenueNet	162354000
CY2016Q3	us-gaap	Net Income Loss NetIncomeLoss	126520000
CY2015Q1	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	79783000	shares
CY2015Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.38
CY2015Q1	us-gaap	Net Income Loss NetIncomeLoss	-30658000
CY2015Q2	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	80203000	shares
CY2015Q2	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.36
CY2015Q2	us-gaap	Net Income Loss NetIncomeLoss	-28910000
CY2016Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.29
CY2016Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	85771000	shares
CY2016Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	85771000	shares
CY2016Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.29
CY2016Q1	us-gaap	Net Income Loss NetIncomeLoss	-24873000
CY2016Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	91061000	shares
CY2016Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	91061000	shares
CY2016Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.33
CY2016Q2	us-gaap	Net Income Loss NetIncomeLoss	-29959000
CY2015Q4	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	83862000	shares
CY2015Q4	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-3.30
CY2015Q4	us-gaap	Net Income Loss NetIncomeLoss	-277020000
CY2015Q4	us-gaap	Asset Impairment Charges AssetImpairmentCharges	242700000
CY2016Q4	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.56
CY2016Q4	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	96510000	shares
CY2016Q4	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	95676000	shares
CY2016Q4	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.56
CY2016Q4	us-gaap	Sales Revenue Net SalesRevenueNet	12404000
CY2016Q4	us-gaap	Net Income Loss NetIncomeLoss	53976000
CY2015Q3	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	81039000	shares
CY2015Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.39
CY2015Q3	us-gaap	Net Income Loss NetIncomeLoss	-31857000
CY2016Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	1.31
CY2016Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	96548000	shares
CY2016Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	95627000	shares

Files In Submission

Name	View Source	Status
0001193125-17-085519-index-headers.html	Edgar Link	pending
0001193125-17-085519-index.html	Edgar Link	pending
0001193125-17-085519.txt	Edgar Link	pending
0001193125-17-085519-xbrl.zip	Edgar Link	pending
d305327d10k.htm	Edgar Link	pending
d305327dex1031.htm	Edgar Link	pending
d305327dex1032.htm	Edgar Link	pending
d305327dex1033.htm	Edgar Link	pending
d305327dex1035.htm	Edgar Link	pending
d305327dex1036.htm	Edgar Link	pending
d305327dex231.htm	Edgar Link	pending
d305327dex31.htm	Edgar Link	pending
d305327dex32.htm	Edgar Link	pending
d305327dex42.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
g305327dsp29.jpg	Edgar Link	pending
g305327dsp30a.jpg	Edgar Link	pending
g305327dsp47.jpg	Edgar Link	pending
g305327g95u55.jpg	Edgar Link	pending
g305327mn3.jpg	Edgar Link	pending
g305327mnkd2.jpg	Edgar Link	pending
mnkd-20161231.xml	Edgar Link	completed
mnkd-20161231.xsd	Edgar Link	pending
mnkd-20161231_cal.xml	Edgar Link	unprocessable
mnkd-20161231_def.xml	Edgar Link	unprocessable
mnkd-20161231_lab.xml	Edgar Link	unprocessable
mnkd-20161231_pre.xml	Edgar Link	unprocessable
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R73.htm	Edgar Link	pending
R74.htm	Edgar Link	pending
R75.htm	Edgar Link	pending
R76.htm	Edgar Link	pending
R77.htm	Edgar Link	pending
R78.htm	Edgar Link	pending
R79.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R80.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$MNKD
MANNKIND CORP Stock $mnkd

2016 Form 10-K Financial Statement

#000119312517085519 Filed on March 16, 2017

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$MNKD MANNKIND CORP Stock $mnkd

2016 Form 10-K Financial Statement

#000119312517085519 Filed on March 16, 2017

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$MNKD
MANNKIND CORP Stock $mnkd